8-(2-chlorophenyl)-6-(4-ethylpiperazin-1-yl)-2-methyl-9H-purine | 1335202-48-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 8-(2-chlorophenyl)-6-(4-ethylpiperazin-1-yl)-2-methyl-9H-purine
• 英文别名: 8-(2-chlorophenyl)-6-(4-ethylpiperazin-1-yl)-2-methyl-7H-purine
• CAS: 1335202-48-6
• 化学式: C₁₈H₂₁ClN₆
• 分子量: 356.858
• InChiKey: BWTWHSMZCKTAOD-UHFFFAOYSA-N

物化性质

• 沸点：
  472.8±55.0 °C(Predicted)
• 密度：
  1.293±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  60.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-(2-chlorophenyl)-6-(4-ethylpiperazin-1-yl)-2-methyl-9H-purine 在 盐酸 作用下， 以 乙醚 、 水 、 丙酮 、 乙腈 为溶剂， 反应 1.0h， 生成 8-(2-chlorophenyl)-6-(4-ethylpiperazin-1-yl)-2-methyl-9H-purine hydrochloride
  参考文献：
  名称：

  Selective Cannabinoid Receptor Type 2 (CB2) Agonists: Optimization of a Series of Purines Leading to the Identification of a Clinical Candidate for the Treatment of Osteoarthritic Pain

  摘要：

  A focused screening strategy identified thienopyrimidine 12 as a cannabinoid receptor type 2 agonist (hCB2) with moderate selectivity over the hCB1 receptor. This initial hit suffered from poor in vitro metabolic stability and high in vivo clearance. Structure-activity relationships describe the optimization and modification to a new more polar series of purine CB2 agonists. Examples from this novel scaffold were found to be highly potent and fully efficacious agonists of the human CB2 receptor with excellent selectivity against CBI, often having no CBI agonist activity at the highest concentration measured (>100 mu M). Compound 26 is a centrally penetrant molecule which possesses good biopharmaceutical properties, is highly water-soluble, and demonstrates robust oral activity in rodent models of joint pain. In addition, the peripherally restricted molecule 22 also demonstrated significant efficacy in the same analgesic model of rodent inflammatory pain.

  DOI：

  10.1021/jm400305d
• 作为产物：
  描述：

  6-氯-2-甲基嘧啶-4,5-二胺 在 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 为溶剂， 反应 34.0h， 生成 8-(2-chlorophenyl)-6-(4-ethylpiperazin-1-yl)-2-methyl-9H-purine
  参考文献：
  名称：

  Selective Cannabinoid Receptor Type 2 (CB2) Agonists: Optimization of a Series of Purines Leading to the Identification of a Clinical Candidate for the Treatment of Osteoarthritic Pain

  摘要：

  A focused screening strategy identified thienopyrimidine 12 as a cannabinoid receptor type 2 agonist (hCB2) with moderate selectivity over the hCB1 receptor. This initial hit suffered from poor in vitro metabolic stability and high in vivo clearance. Structure-activity relationships describe the optimization and modification to a new more polar series of purine CB2 agonists. Examples from this novel scaffold were found to be highly potent and fully efficacious agonists of the human CB2 receptor with excellent selectivity against CBI, often having no CBI agonist activity at the highest concentration measured (>100 mu M). Compound 26 is a centrally penetrant molecule which possesses good biopharmaceutical properties, is highly water-soluble, and demonstrates robust oral activity in rodent models of joint pain. In addition, the peripherally restricted molecule 22 also demonstrated significant efficacy in the same analgesic model of rodent inflammatory pain.

  DOI：

  10.1021/jm400305d

文献信息

• PURINE COMPOUNDS
  申请人：SANDERSON Adam Jan

  公开号：US20110245255A1

  公开（公告）日：2011-10-06

  A compound of the formula: and pharmaceutical compositions for the treatment or prevention of pain.

  该化合物的化学式，以及用于治疗或预防疼痛的药物组合。
• Purine compounds
  申请人：Sanderson Adam Jan

  公开号：US08759360B2

  公开（公告）日：2014-06-24

  A compound of the formula: and pharmaceutical compositions for the treatment or prevention of pain.

  该化合物的化学式为：该化合物及其药物组合物可用于治疗或预防疼痛。
• Discovery and optimization of novel purines as potent and selective CB2 agonists
  作者：Sean P. Hollinshead、Peter C. Astles、Mark G. Chambers、Michael P. Johnson、John Palmer、Michael W. Tidwell

  DOI：10.1016/j.bmcl.2012.06.035

  日期：2012.8

  A focused screening strategy identified thienopyrimidine 1 as a hCB2 cannabinoid receptor agonist with moderate selectivity over the hCB1 receptor. This initial hit suffered from poor in vitro metabolic stability and high in vivo clearance. Structure-activity relationships describe the optimization and modification to a less lipophilic purine core. Examples from this novel series were found to be highly potent and fully efficacious agonists of the human CB2 receptor with excellent selectivity against CB1. Compound 10 possesses good biopharmaceutical properties, is highly water soluble and demonstrates robust oral activity in rodent models of joint pain. (c) 2012 Elsevier Ltd. All rights reserved.
• US8759360B2
  申请人：——

  公开号：US8759360B2

  公开（公告）日：2014-06-24
• [EN] PURINE COMPOUNDS<br/>[FR] COMPOSÉS DE PURINE
  申请人：LILLY CO ELI

  公开号：WO2011123372A1

  公开（公告）日：2011-10-06

  A compound of the formula (I) and pharmaceutical compositions for the treatment or prevention of pain.